Apimeds Pharmaceuticals US (APUS) Non-Current Assets (2025)
Apimeds Pharmaceuticals US's (APUS) quarterly Non-Current Assets came in at $150.2 million in Q4 2025, up 91525.52% on a QoQ basis from $163928.0 in Q3 2025.
Apimeds Pharmaceuticals US (APUS) Non-Current Assets (2025) Analysis & Trends
Apimeds Pharmaceuticals US (APUS) has 1 years of Non-Current Assets data on file, last reported at $150.2 million in Q4 2025.
- Quarterly Non-Current Assets changed N/A year-over-year to $150.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $150.6 million (changed N/A YoY) and the FY2025 annual result came in at $150.2 million, changed N/A from the prior year.
- Non-Current Assets grew to $150.2 million in Q4 2025, from $163928.0 in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $150.2 million in Q4 2025 to a low of $163928.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 2.96 Bn |
| 10 | Apimeds Pharmaceuticals US | 7.50 Mn | 7.50 Mn | - | 116.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 150.20 Mn |
| Sep 30, 2025 | 163,928.00 |
| Jun 30, 2025 | 197,132.00 |